[Experiences with the realisation of innovative study designs using the example of the HOPE-study].
Rangoonwala
B
B
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D004311:Double-Blind Method; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000517:prevention & control; D010919:Placebos; D017257:Ramipril / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D012107:Research Design / Q000592:standards* / Q000639:trends; D012307:Risk Factors; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D010919:Placebos; D017257:Ramipril